I want sex, but struggle to orgasm. Could PT-141 help?
In this article
Bremelanotide, also called PT-141, has encouraging findings for orgasm in premenopausal women being treated for low desire. It has not been established as a treatment for orgasm difficulty on its own. The key question is whether your concern involves desire, arousal, orgasm, or a combination. 2025 RECONNECT analysis.
If you enjoy sex but reaching orgasm takes longer than you want, happens less often, or feels out of reach, you can ask for help with that specific experience.
Desire, arousal, and orgasm are different questions
| Part of the experience | A way to describe your concern |
|---|---|
| Desire | “I rarely feel interested in starting.” |
| Arousal | “I want sex, but struggle to feel mentally or physically excited.” |
| Orgasm | “I feel interested and aroused, but reaching orgasm is difficult.” |
These concerns can overlap. They can also call for different approaches. ACOG identifies desire, arousal, orgasm, and pain as distinct areas to explore during sexual-health care. ACOG sexual-health guidance.
You might want easier orgasms, more satisfying sensations, or less worry about whether orgasm will happen. Describe what matters to you in your own words.
What does the PT-141 research show?
A 2025 conference abstract examined previously unreported questionnaire results from the two RECONNECT trials. Women receiving branded bremelanotide reported greater improvements in arousal and orgasm scores than those receiving placebo, beginning at the first assessment and continuing through the study.
These promising findings came from premenopausal women with hypoactive sexual desire disorder, or HSDD, in an industry-funded secondary analysis. This was not a dedicated trial of isolated orgasm difficulty, and it does not establish equivalent effects in men, medication-related sexual dysfunction, or compounded preparations. 2025 conference abstract.
In the original RECONNECT report, other female sexual dysfunctions were excluded. The main benefits were improved desire scores and reduced distress related to low desire. The number of satisfying sexual events did not significantly improve compared with placebo. Original trial report.
For men, a separate 2025 clinic report included only four bremelanotide users: one reported resolution, one partial improvement, and two had either no improvement or no follow-up. That is a reason to investigate further, not enough evidence to predict someone’s response. Male orgasmic-disorder report.
What should an assessment explore?
Make a few notes before an appointment:
- Did this begin recently, or has orgasm always been difficult?
- Does it happen during solo activity, partnered activity, or both?
- Is desire present? Are arousal and physical comfort where you want them to be?
- Did anything change around the same time, including a medication, illness, or surgery?
- Which experiences feel satisfying, even when orgasm does not happen?
For men with delayed ejaculation, urology guidance recommends a medical, relationship, and sexual history, a focused examination, and testing when indicated. Describe orgasm and ejaculation separately if one occurs without the other. AUA/SMSNA guideline.
Bring your medication list, including what is working well for you. Ask for a plan before changing a prescription yourself.
What else can you explore?
Treatment should follow the concern being evaluated. That may involve medication review, addressing pain, or working with a qualified sex therapist. More time for stimulation, different kinds of stimulation, and sex toys are among the approaches ACOG describes for orgasm difficulties. ACOG sexual-health options.
If dryness or discomfort is part of the change, our guide to sexual health after menopause explains why comfort deserves its own assessment.
If you have a partner, you could start with: “I want us to make more room for what feels good to me. Here is something I would like to try.” You can also say, “I would like to enjoy this without checking whether I am close yet.”
You get to decide what satisfying sex means for you. Wanting to reach orgasm is valid. Enjoying sex without making orgasm the requirement is valid, too.
What about AnthologyRX’s preparation?
AnthologyRX’s compounded PT-141 contains bremelanotide, the active ingredient in Vyleesi, and is prepared by a licensed pharmacy to an individual prescription. It is not FDA-approved or established as equivalent to the branded product. Treatment details; FDA compounding information.
Vyleesi is approved for acquired, generalized HSDD in premenopausal women, not orgasm difficulty or sexual-performance enhancement. Its labeling contraindicates use with uncontrolled hypertension or known cardiovascular disease. Risks include nausea, temporary blood-pressure increases, skin darkening, and altered absorption of oral medicines. Oral naltrexone has a specific warning. Prescribing information.
Questions you may be asking
Does improved orgasm scoring mean stronger orgasms?
A questionnaire-domain improvement reports a group result on a particular measure. It does not establish that an individual’s orgasms will be stronger, faster, or more frequent.
Can PT-141 help if an antidepressant caused the problem?
The main RECONNECT trials excluded people taking antidepressants and do not establish a benefit for antidepressant-related orgasm difficulty. Bring the timing of your symptoms to the clinician managing that medication. Trial eligibility criteria.
Do I have to wait until I can never orgasm to ask for help?
You can ask about a change that bothers you now. Explain what happens, how it affects you, and what you would like to be different.
If PT-141 interests you, explore the treatment and assessment details and our PT-141 safety guide.
